While Lupin and Marksans Pharma are recalling diabetes drug, Aurobindo and Alembic are recalling psychiatric medication in the US market.

The group has more than 243 approvals, and so far filed over 330 abbreviated new drug applications (ANDAs) since it started filings in 2003...

I expect the price erosion to continue in America in the first two quarters at least for the current year before it stabilises around 8-10%.

MD Pranav Amin said: "Our base business in the US is doing well. We will continue to invest in R&D for future growth and have spent Rs 117 ...

Consolidated total income from operations during the quarter under review also fell to Rs 777.03 crore from Rs 930.89 crore a year ago.

Interestingly, the growth came during the period when biggies like Sun Pharma and Dr Reddy's had reduced filings from their plants due to c...

The annual report released by the FDA’s OGD shows Indian companies have won some key approvals in the world’s biggest pharmaceuticals marke...

Alembic Pharmaceuticals reported nearly 4-fold jump in its consolidated net profit to Rs 269.49 crore for the quarter ended December 31.

Shares of Aurobindo Pharma climbed five per cent today as the company has received final approval from the US health regulator FDA to manuf...

People close to the transaction said Cipla will buy Invagen and Camber, Hetero’s wholly owned subsidiary, for about $550 million.

"Cipla's portfolio is of a commodity generics type; so this will definitely place it in a strong position in terms of product pipeline in t...

Indian markets are expected to trade in a range. Here is a list of fifteen stocks which are likely to be in focus today.

According to pharma analyst, the company would continue to witness jump in its stock prices as it is bullish on getting FDA approval for it...

The company got a tentative approval for aripiprazole orally disintegrating tabs in the strengths of 10 mg, 15 mg, 20 mg and 30 mg.